GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 110 participants.
Also called NCT05356104
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 110 participants
- Registry
-
NCT05356104
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China, Hong Kong SAR China
- Registry status
- Recruiting
Technical summary
Registry record NCT05356104. Randomized; single masking; primary purpose treatment. Start 2022-05-25 (actual); primary completion 2027-05 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)
- Acronym
- GAPP-SVD
- Condition
- Cerebral Small Vessel Disease
- Intervention (Drug)
- GLP-1 receptor agonist
- Lead sponsor
- Chinese University of Hong Kong
- Collaborator
- First Affiliated Hospital of Wenzhou Medical University
Record details
- Record id
cardio:ct-nct05356104- Content hash
573eb6e3a144878646d8841fa6a288a1d8030b13b4166e5732b82f07794f88b2